<DOC>
	<DOCNO>NCT01993641</DOCNO>
	<brief_summary>The purpose open label study determine whether combine pracinostat ( study drug ) Vidaza ( azacitidine ) Dacogen ( decitabine ) improve clinical response Myelodysplastic Syndrome ( MDS ) patient fail initial single agent hypomethylating agent ( HMA ) , provide additional safety efficacy data .</brief_summary>
	<brief_title>Phase 2 Study Adding Pracinostat Hypomethylating Agent ( HMA ) Patients With MDS Who Failed Respond Single Agent HMA</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Voluntary write informed consent 2 . Histologically cytologically document diagnosis MDS ( FrenchAmericanBritish classification [ FAB ] subtype ) 3 . Bone marrow blast &gt; 5 % &lt; 30 % peripheral white blood cell ( WBC ) count &lt; 20,000 /µL 4 . Bone marrow biopsy , aspirate , peripheral blood smear within 28 day first study treatment 5 . Group 1 : Primary failure : Progression recent HMA therapy accord IWG criterion receive single agent azacitidine and/or single agent decitabine , worsen cytopenia ( increased transfusion requirement ) , increase BM blast , progression high FAB type , develop additional clinically significant cytogenetic abnormality ; Secondary failure : Relapse initial CR , PR , HI , development clinically significant cytogenetic abnormality time accord IWG criterion receive single agent azacitidine decitabine Group 2 : Failure achieve response ( CR , PR HI ) accord IWG criterion definition stable disease recent HMA therapy ( least 6 cycle azacitidine 4 cycle decitabine ) 6 . Must demonstrate tolerability single agent HMA 7 . Able start combination therapy within 3 month last single agent HMA dose therapy disease study receive interval 8 . Not candidate hematopoietic stem cell transplant within 4 month screen 9 . ECOG performance status 0 , 1 , 2 10 . Adequate organ function evidence : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x upper limit normal ( ULN ) Total bilirubin ≤1.5 x ULN total bilirubin ≤2 mg/dL , whichever high Serum creatinine &lt; 2 mg/dL , creatinine clearance ≥60 mL/min QTcF interval ≤470 msec 11 . Female male patient ≥18 yearsofage 12 . Male patient female partner require use two form acceptable contraception ; Female patient childbearing potential must negative pregnancy test ≤7 day first study treatment . 13 . Willingness ability understand nature trial comply 1 . Received follow within specified time frame last single agent HMA dose first administration study medication : Any therapy malignancy time single agent HMA first onstudy treatment Hydroxyurea within 48 hour prior first study treatment Hematopoietic growth factor : erythropoietin , granulocyte colony stimulate factor ( GCSF ) , granulocyte macrophage colony stimulate factor ( GMCSF ) , thrombopoietin receptor agonist within 7 day ( 14 day Aranesp ) prior first study treatment Major surgery within 28 day study day 1 2 . Patients candidate aggressive chemotherapy ( e.g . typical AML induction therapy ) 3 . Cardiopulmonary function criterion : Current unstable arrhythmia require treatment History symptomatic congestive heart failure ( New York Heart Association Class III IV ) History myocardial infarction within 6 month enrollment Current unstable angina 4 . Concomitant treatment agent activity HDAC inhibitor permit 5 . Clinical evidence CNS involvement 6 . Patients gastrointestinal ( GI ) tract disease , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) 7 . Active infection human immunodeficiency virus chronic hepatitis B C 8 . Lifethreatening illness unrelated cancer serious medical psychiatric illness could potentially interfere participation study 9 . Presence malignant disease within last 12 month , exception adequately treat insitu carcinoma , basal squamous cell carcinoma , nonmelanomatous skin cancer concurrent malignancy consider case case basis 10 . Inability unwillingness ( include psychological , familial , sociological , geographical condition ) comply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>pracinostat</keyword>
	<keyword>Hypomethylating Agent</keyword>
	<keyword>HMA</keyword>
	<keyword>azacitadine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>decitabine</keyword>
	<keyword>dacogen</keyword>
</DOC>